Comparison of Different Dyspnea Scales and Questionnaires with Six Minute Walk Test and Lung Function Tests in Symptomatic COPD Patients.

COVID-19 ARDS has a high mortality and few therapeutic options. We present a preliminary report on our experience using high-dose pulsed methylprednisolone in COVID-19 ARDS and three-month outcomes. We performed a retrospective analysis of all patients treated with high-dose methylprednisolone for COVID-19 ARDS and three-month lung function, 6MWT, and CT findings. 15 patients were treated of which 10 survived to discharge. Reduced DLCO was the commonest abnormality in lung function tests and had the lowest mean value. Parenchymal bands were the commonest CT finding and 50% of patients had fibrosis at three-months. Mean 6MWD was 65.4% predicted and was abnormal in 62.5% of patients. In this cohort of patients with COVID-19 ARDS treated with high-dose methylprednisolone pulses, CT, lung function, and 6MWT abnormalities were unsurprisingly common at three months, although all 10 patients treated early in their disease course survived, a possible therapeutic effect. Further randomised controlled trials are needed to assess the benefits of this treatment.

Download Full-text

Correlation of spirometry and six minute walk test in patients with chronic obstructive pulmonary disease from Sundargarh, Odisha, India

International Journal of Research in Medical Sciences ◽

10.18203/2320-6012.ijrms20195908 ◽

2019 ◽

Vol 8 (1) ◽

pp. 205

Author(s):

Yara Dinakar ◽

Pradeep Panchadi Kiran ◽

Akshaya K. Mohanty ◽

Praveen Kishore Sahu ◽

Anita Mohanty

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Significant Positive Correlation ◽

Significant Negative Correlation ◽

Chronic Obstructive ◽

Walk Test ◽

Obstructive Pulmonary Disease ◽

Positive Correlation ◽

Six Minute Walk Test ◽

Copd Patients ◽

Minute Walk

Background: Six‑Minute Walk Test (6MWT) is a simple, objective, reproducible test which correlated well with different spirometric indices, and thus able to predict severity of Chronic Obstructive Pulmonary Disease (COPD) and can replace spirometry in resource poor set‑up. Here, author evaluated the correlation of 6 minute walk distance (6MWD) with spirometric indices in COPD patients and the potential of 6MWT as an alternative to the assessment of severity of COPD.Methods: This cross-sectional observational study included a total of 80 COPD patients, diagnosed by GOLD criteria (Post bronchodilator FEV1/ FVC ratio <0.7). Modified Medical Research Council (mMRC) grading was used (age, weight, height, body mass index- BMI and breathlessness) and all the patients underwent spirometric measurement of FEV1, FVC and FEV1/ FVC ratio and tests were repeated after bronchodilation using 200-400 μg of salbutamol. 6MWT was performed following American Thoracic Society (ATS) protocol of 6MWT and distance was measured in meters.Results: Author found significant negative correlation of 6MWT with age (r=-0.384, p=0.00) and mMRC grading of dyspnea (r=-0.559, p=0.00) and significant positive correlation with height (r=0.267, p=0.019) and weight (r=0.293, p=0.008). Significant positive correlation of 6MWD was noted with post bronchodilator FEV1(r=0.608, p=0.00), FEV1% (r=0.429, p=0.00), FVC (r=0.514 p=0.00), FVC% (r=0.313 p=0.005), FEV1/FVC % (r=0.336, p=0.001). Positive correlation was also observed between 6MWT and BMI but statistically insignificant (r=0.177, p=0.116). There was significant negative correlation between 6MWT and GOLD staging (r=-0.536, p=0.00).Conclusions: This finding concludes that 6MWT can be used for the assessment of severity of disease in COPD patients in places where spirometry is not available.

Download Full-text